Thrombolysis plus aortic counterpulsation: Improved survival in patients who present to community hospitals with cardiogenic shock

Journal of the American College of Cardiology

Volumn 29, Issue 7, 1997, Pages 1454-1458

  Kovack, Paul J ^a   Rasak, Mark A ^a   Bates, Eric R ^b   Ohman, E Magnus ^c   Stomel, Robert J ^a  

^a Garden City Hospital   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; COUNTERPULSATION; DIAGNOSTIC ACCURACY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG CAPILLARY; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; SURVIVAL RATE;

EID: 0030976236     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)82537-5     Document Type: Article

References (26)

1. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction incidence and mortality from a community wide perspective 1995-1988 . N Engl J Med. 325:1991;1117-1122.
2. Effectiveness of intravenous treatment in acute myocardial infarction. Lancet. 1:1986;397-401.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction. Lancet. 2:1988;349-360.
4. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of mortality and major morbidity results from all randomised trials of more than 1000 patients . Lancet. 343:1994;311-322.
5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
6. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 336:1990;71-75.
7. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock the GUSTO-I trial experience . J Am Coll Cardiol. 26:1995;668-674.
8. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol. 18:1991;1077-1084.
9. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 20:1992;1626-1633.
10. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N Engl J Med. 329:1993;1615-1622.
11. O'Rourke MF, Norris RM, Campbell TJ, Chang VP, Sammel NL. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol. 47:1981;815-820.
12. Flaherty JT, Becker LC, Weiss JL, et al. Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction. J Am Coll Cardiol. 6:1985;434-446.
13. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med. 85:1988;353-359.
14. Anderson RD, Stebbins AL, Bates E, Stomel R, Granger CB, Ohman EM. Underutilization of aortic counterpulsation in patients with cardiogenic shock observations from the GUSTO-I study [abstract] . Circulation. 92 Suppl I:1995;I-139.
15. Silverman AJ, Williams AM, Wetmore RW, Stomel RJ. Complications of intraaortic balloon counterpulsation insertion in patients with thrombolytic therapy from acute myocardial infarction. J Invas Cardiol. 4:1991;49-52.
16. Goodwin M, Hartmann J, Mikeever L, et al. Safety of intraaortic balloon counterpulsation in patients with acute myocardial infarction receiving streptokinase intravenously. Am J Cardiol. 64:1989;937-938.
17. Stomel RJ, Rasak MA, Bates ER. Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital. Chest. 105:1994;997-1002.
18. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. 20:1992;1482-1489.
19. Moscucci M, Bates ER. Cardiogenic shock. Cardiol Clin. 13:1995;391-406.
20. Allen BS, Buckberg GD, Fontan FM, et al. Superiority of controlled surgical reperfusion versus percutaneous transluminal coronary angioplasty in acute coronary occlusion. J Thorac Cardiovasc Surg. 105:1993;864-879.
21. Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol. 23:1994;794-798.
22. Kern MJ, Aguirre FV, Tatineni S, et al. Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients. J Am Coll Cardiol. 21:1993;359-368.
23. Nanas JN, Nanas SN, Kontoyannis DA, et al. Myocardial salvage by the use of reperfusion and intraaortic balloon pump experimental study . Ann Thorac Surg. 61:1996;629-634.
24. Gurbel PA, Anderson RD, MacCord CS, et al. Arterial diastolic pressure augmentation by intraaortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. Circulation. 89:1994;361-365.
25. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 342:1993;759-766.
26. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 342:1993;767-772.